PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Acad Emerg Med. Author manuscript; available in PMC 2013 June 1.
Published in final edited form as:
PMCID: PMC3375948
NIHMSID: NIHMS366806

Risk Factors for Increased ED Utilization in a Multinational Cohort of Children with Sickle Cell Disease

Abstract

Objectives

To identify clinical, social, and environmental risk factors for increased emergency department (ED) use in children with sickle cell disease (SCD).

Methods

This study was a secondary analysis of ED utilization data from the international multicenter Silent Cerebral Infarct Transfusion (SIT) trial. Between December 2004 and June 2010, baseline demographic, clinical, and laboratory data were collected from children with SCD participating in the trial. The primary outcome was the frequency of ED visits for pain. A secondary outcome was the frequency of ED visits for acute chest syndrome.

Results

The sample included 985 children from the US, Canada, England, and France, for a total of 2,955 patient-years of data. There were 0.74 ED visits for pain per patient-year. A past medical history of asthma was associated with an increased risk of ED utilization for both pain (RR = 1.28, 95% CI = 1.04 to 1.58) and acute chest syndrome (RR = 1.60, 95% CI = 1.03 to 2.49). Exposure to environmental tobacco smoke in the home was associated with 73% more ED visits for acute chest syndrome (RR 1.73, 95% CI = 1.09 to 2.74). Each $10,000 increase in household income was associated with 5% fewer ED visits for pain (RR 0.95, 95% CI = 0.91 to 1.00, p = 0.05). The association between low income and ED utilization was not significantly different in the USA vs. countries with universal health care (p = 0.51).

Conclusions

Asthma and exposure to environmental tobacco smoke are potentially modifiable risk factors for greater ED use in children with SCD. Low income is associated with greater ED use for SCD pain in countries with and without universal health care.

INTRODUCTION

Sickle cell disease (SCD) is an inherited disorder of hemoglobin that affects approximately 100,000 Americans.1 In affected individuals, hemoglobin forms rigid polymers in response to tissue hypoxia or stress, which gives erythrocytes a sickle shape. Etiology for vaso-occlusive pain episodes is not completely understood, but evidence suggests inflammation and other rheologic processes (coagulation and platelet activation, endothelial dysfunction) contribute to increased cell adhesion, which leads to vasoocclusion and ultimately, clinical manifestations of SCD.27 The hallmark of the disease and the most frequent reason for ED visits is the vasoocclusive crisis,8 marked by paroxysmal attacks of debilitating pain. A leading cause of death is the acute chest syndrome,9 marked by pulmonary infiltrate, fever, and respiratory distress. Despite being a monogenic disorder, wide clinical variation in the severity of SCD exists, suggesting that non-genetic factors contribute. Individuals with severe disease suffer frequent complications and early mortality, while others can live into their eighth decade. Clinical, environmental, and social factors are now believed to contribute to SCD morbidity, and this has prompted interrogation of modifiable risk factors for increased health care utilization.

In children with SCD, comorbid asthma is associated with higher rates of hospital admissions for pain, acute chest syndrome, and death;1012 however, the relationship between comorbid asthma and ED use for SCD has not been adequately explored. The presumed mechanism is that asthma increases complications of SCD via the convergence of the two inflammatory processes.13,14 Inflammation of the airways (asthma) and inflammation of the endothelium (SCD) are synergistic and thus the balance is tipped toward increased vasoocclusion. Transgenic mice with SCD have increased airway inflammation at baseline,15 and show greater increases in pulmonary inflammation than wild type mice when experimental models of asthma are induced.16 Human data support these findings, as individuals with SCD have high rates of airway hyper-reactivity even in the absence of asthma.17 Demonstration that asthma is associated with increased ED utilization for SCD would provide support for future research to evaluate asthma interventions (both ED- and clinic-based) that could reduce SCD morbidity and ED use.

Poverty has been identified as a significant threat to the health of all Americans (attributed to cause 133,000 deaths in the United States each year),18 but the data regarding the effects of income on SCD are mixed. Prior studies using Medicaid insurance as a proxy for lower income showed an increase in health care utilization among children with SCD enrolled in Medicaid compared to those with private insurance.19,20 In contrast, a prospective study of 232 adults with SCD followed for a mean of 4.4 months did not find statistically significant differences in income or education levels between low and high users of ED care.21 Identification of poverty in this cohort as a risk factor for ED use would suggest that even low-income families with subspecialty follow-up are at increased risk.

The objective of this study was to identify factors associated with increased ED utilization in children with SCD. This study represents an analysis of ED utilization data from a multinational cohort of children participating in a prospective clinical trial. As all children in the study receive high-quality subspecialty care, these data provide information about risk factors for ED utilization and SCD morbidity when issues of access to and quality of care are removed. Our hypotheses are that low income and comorbid asthma are associated with increased ED use. A secondary objective was to explore the association between income and ED utilization in countries with and without universal access to health care. Further understanding of the associations between ED utilization and risk factors such as asthma and income may enable clinicians to better target high-risk groups for intervention.

METHODS

The Silent Cerebral Infarct Transfusion (SIT) Trial

The SIT trial includes 25 active clinical sites located in North America (US and Canada) and Europe (U.K. and France). The primary aim of the trial was to test the hypothesis that prophylactic blood transfusion therapy in children with silent cerebral infarcts (SCI) will result in at least an 86% reduction in the rate of subsequent overt strokes or new or progressive cerebral infarcts as defined by magnetic resonance imaging (MRI) of the brain. Details of the recruitment were described in the recently published study design manuscript for the SIT Trial (clinicaltrials.gov Identifier: NCT00072761).22 Between December 2004 and June 2010, baseline demographic, clinical, and laboratory data were collected from children participating in the trial and kept in an SPSS database (IBM SPSS, Armonk, NY). Analysis of these baseline data are the subject of this article. The SIT trial was approved (including a positive pre-study review) by the institutional review boards of all participating sites. Written informed consent was obtained from caretakers and verbal assent from each participant.

Study Design

This study was a post-hoc analysis of potential predictor variables for ED use among subjects enrolled in the SIT trial. The primary outcome of our analysis, incidence rate of ED visits for pain, was determined by chart review of each subject encompassing the three years prior to enrollment in the SIT trial. Baseline demographic (including self-reported income, race, sex, and other socio-demographic variables via cross-sectional survey), clinical (co-morbidities, prior illnesses, medication use, and other clinical variables via cross-sectional survey), and laboratory data were prospectively collected at the time of enrollment. Children were enrolled between December 2004 and June 2010. This secondary analysis was approved by the executive committee of the SIT trial and the data safety monitoring board appointed by the National Institute of Neurological Disorders and Stroke.

Study Setting and Population

Tertiary medical centers with multidisciplinary SCD services at 25 sites in Canada, England, France, and the United States were included. Patients with hemoglobin SS (94%) or Sβ zero (6%), the most severe types of SCD, were recruited between 5 and 14 years of age. Children included did not have any evidence of overt stroke, were not on regular blood transfusion therapy, and were not receiving hydroxyurea therapy. An entry criterion of the study was an ongoing prior relationship with the physicians of the hematology service at participating clinical sites. This criterion was instituted because of the intensity of the clinical trial, requiring patients who were randomized to the treatment arm of the trial to receive blood transfusion therapy for 36 months. Children who did not have an existing relationship with the hematology service (as determined by the site director) were not enrolled in the study.

Study Protocol

Training of Chart Abstractors

Before the chart abstraction was performed, all site coordinators and auditors were trained in the methods of chart abstraction. Definitions for key variables and all data abstraction forms were reviewed. Individual chart abstractors (research nurses) were trained by site coordinators. For each individual in the SIT trial, charts were reviewed for all visits to the medical center for the three years prior to signing consent. Before the start of the study, coordinators at all sites agreed to case definitions for outcome variables, including ED visit, hospital admission, painful episode, and acute chest syndrome. Periodic meetings were held with study coordinators to review coding rules and ensure accurate and uniform chart abstraction procedures. Chart abstractors were blinded to the hypothesis for this study.

The primary outcome for this study was the number of ED visits for painful episodes. An ED visit was defined as any visit to the ED, including patients who were admitted to the hospital and those who were discharged home. A painful episode was defined as an ED visit that required treatment with opiates that could not be attributable to a cause other than SCD. A secondary outcome for this analysis was the number of ED visits for acute chest syndrome, defined as a pulmonary process (abnormal chest radiograph) that required admission to the hospital.23 Pneumonia was indistinguishable from acute chest syndrome, and thus considered an episode of acute chest syndrome in this analysis. Visits that met criteria for both painful episode and acute chest syndrome were recorded as acute chest syndrome. For each patient, all acute chest syndrome and pain episodes in the three years prior to signing informed consent were extracted from the medical record at the patient’s trial site.

Classification of Income

Participants self-reported their yearly household income in $10,000 increments up to $100,000, with additional categories for $100,000 – $150,000 and greater than $150,000. For trial sites outside the United States, income was converted to U.S. dollars on the day the information was recorded. Participants also indicated the number of people living in their households. The 2010 Health and Human Services poverty guidelines for the 48 contiguous states provide different cut-points for the federal poverty line based on the number of people in a given household (Data Supplement 1).24 Using the number of people in each individual’s household, income was re-coded into a dichotomous variable indicating whether or not the patient lived below the federal poverty line. Per-capita income for each participant’s household was calculated by dividing unadjusted household income by the number of people living in that household.

Asthma

Asthma was defined as the parent or guardian answering “yes” to the question: “Did a doctor ever say the patient has asthma?” The use of asthma medication was also recorded. When a diagnosis of asthma was made and no asthma medication was recorded in the SIT Trial database, we confirmed the diagnosis of asthma with a review of the medical records by the site coordinator for any hospital admissions, ED visits, or medications for asthma. Similarly, if the patient was recorded in the medical records as having prescriptions for inhaled corticosteroids, bronchodilators, or a cysteinyl leukotriene receptor antagonist, but the parent did not state that the child had asthma, the site coordinator was required to recheck the medical records for a diagnosis of asthma. An assumption was made that asthma is a chronic condition.25

All data were recorded onto the SIT Demographic and Phenotypic form and entered into a SPSS database. Performance of chart abstractors was checked regularly by site coordinators and audited during site visits by the primary investigator. All laboratory values and clinical parameters were checked for outliers and missing data. Specifically, based on the distribution, each value below the 5th percentile and above the 95th percentile was re-confirmed for accuracy at the local site, and when discrepant, was changed accordingly. For all missing key variables, additional contact was made with the local site coordinator to determine if the data were not available or simply not recorded. Interrater reliability of chart abstraction was not assessed. Instead, all values below the 5th percentile and above the 95th percentile were re-confirmed by a second reviewer at the local site.

Data Analysis

All data analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). Missing values were estimated using a multiple imputation approach,26,27 in which five data sets were created (data regarding missing variables are listed in Figure 1). T-tests and chi-square tests were used to compare mean differences (of normally distributed variables) and proportions when appropriate. Multivariable negative binomial regression models were used to estimate adjusted rate ratios for ED visits. Separate models were run using ED visits for pain and ED visits for acute chest syndrome as the outcome variable. Alpha was set at 0.05 for the primary and secondary analyses. Variables with biologically plausible, known associations with SCD morbidity were included in the multivariable model. In addition to income and trial site, covariates considered for inclusion included age, sex, sickle cell genotype, asthma diagnosis, steady state hemoglobin, steady state leukocyte count, fetal hemoglobin percent, and the presence of tobacco smokers living in the home.28 Because income and insurance status were collinear among participants from U.S. sites, insurance status was not included in the multivariable models. Continuous variables were modeled with linear or quadratic terms when appropriate. According to a pre-specified protocol for regression analyses of SIT trial data, only covariate terms with p values below 0.2 remained in the final regression models. To assess if the effect of family income was significantly different in countries with universal health care vs. the USA, a test for heterogeneity of effect was performed.

Figure 1
Patient Selection

RESULTS

Characteristics of Study Subjects

Of 1,003 participants in the SIT trial at the time of analysis, 18 did not have data regarding ED visits for pain, and 12 were missing data regarding ED visits for acute chest syndrome (Figure 1). Thus, the sample included 985 subjects with a total of 2,955 patient-years of data, 2,201 visits for pain (0.74 per patient-year), and 193 visits for acute chest syndrome (0.06 per patient-year). Baseline characteristics of the cohort are listed in Table 1. The mean age was 9 years and the cohort was 52% male. Nearly one-quarter (24.4%) of patients had a diagnosis of asthma. The median yearly household income was $25,000 with a median of four individuals per household. Among U.S. children, more than half (53.7%) of children in the cohort live below the poverty line, 71% were insured by Medicaid, 33% had private insurance, and 1% were uninsured.

Table 1
Clinical Characteristics and Demographic Data

Main Results

Asthma and Low Self-Reported Income are Associated with Increased ED Use for Pain

Table 2 lists ED use by income category, and Table 3 shows results of the multivariable models. Asthma was associated with a 28% increase in the frequency of ED visits for pain (RR 1.28, 95% CI = 1.04 to 1.58, p = 0.02). There was an inverse relationship between income and ED use for pain (Figure 2). Each $10,000 increase in income was associated with a 5% reduction in ED visits (RR 0.95, 95% CI = 0.91 to 1.00, p = 0.05 – Table 3). A separate multivariable model showed that income below the federal poverty line was associated with a 31% increase in ED visits for pain (RR 1.31, 95% CI = 1.04 to 1.64, p = 0.02). The relationship between per-capita income and rate of painful crises was not statistically significant (RR 0.87, 95% CI = 0.75 to 1.01, p = 0.07). Other variables significantly associated with ED use for pain were fetal hemoglobin percent and trial site (Table 3).

Figure 2
Association between Categories of Household Income and ED Use for Pain
Table 2
ED Utilization Rates by Income Category
Table 3
Negative Binomial Regression Models of ED Visits for Pain and Acute Chest Syndrome

Environmental Tobacco Smoke and Asthma are Associated with Increased ED Use for ACS

The two variables associated with increased risk of ED utilization for acute chest syndrome were asthma and environmental tobacco smoke exposure. Exposure to environmental tobacco smoke within the home was associated with a 73% increase in the rate of ED utilization for acute chest syndrome (RR 1.73, 85% CI = 1.09 to 2.74, p = 0.02) and a physician diagnosis of asthma was associated with a 60% increase in ED visits for acute chest syndrome (RR 1.60, 95% CI = 1.03 to 2.49, p = 0.04). A diagnosis of HbSβThalassemia0 was associated with a significantly reduced risk of acute chest syndrome (RR 0.29, 95% CI = 0.09 to 0.93, p = 0.04). Income and other variables thought to be associated with SCD morbidity were not significantly associated with ED utilization for acute chest syndrome (Table 3).

The Effect of Income on ED Use is not Significantly Different in Countries with Universal Health Care

A test for heterogeneity of effect to determine if the effect of income on ED utilization was different in countries with universal health care was not statistically significant (p = 0.51). Rates of ED use for pain (0.76 vs. 0.68, p = 0.06) and ACS (0.07 vs. 0.06, p = 0.17) were not significantly different between the USA and international trial sites (Table 2).

DISCUSSION

This study represents an analysis of clinical, environmental, and socioeconomic risk factors for ED utilization in a cohort of children who receive high quality subspecialty care as part of a clinical trial. Asthma and low income were associated with higher rates of ED use for pain, and the two greatest risk factors for acute chest syndrome were asthma and exposure to environmental tobacco smoke in the home. These results have import for future research. The magnitude of these associations may be greater in the general population of children with SCD.

Our group has demonstrated that children with SCD who also have asthma have higher hospitalization and mortality rates,10,11 and that asthma exacerbations may precipitate painful episodes,12 but ED use had not been specifically studied. As expected, asthma was associated with increased ED utilization for SCD. Asthma was the only variable associated with increased ED utilization for both pain and acute chest syndrome in the SIT cohort. The magnitude of this association may be even greater in children without access to subspecialty follow-up. Future multi-modal interventions may include aggressive management of asthma in the ED, more frequent follow-up visits for children with asthma, and targeted support for children who live in poverty. Until prospective trials are conducted, we recommend that clinicians carefully assess SCD patients for signs and symptoms of asthma, and closely follow recommended guidelines for the management of asthma in the ED.

Statistically significant associations were noted for household income and living below the federal poverty line and the painful episode rate; however, the association between per-capita income and ED utilization for pain was not statistically significant. These results suggest, but do not confirm, that there is a minimum threshold of family income, where regardless of the number of individuals that live in the house, living below the federal poverty line results in an increase in ED utilization. Another possible source for the discrepancy is the methodology used for calculating household per-capita income.

Our analysis was also designed to test the hypothesis that the association between low self-reported income and ED use would not be present in trial sites with universal access to health care. However, we did not find evidence to support this hypothesis. These data suggest that regardless of location and access to health care, children with SCD who live in low-income households have higher rates of ED utilization. This relationship may be mediated directly through deleterious effects of the physical environment and the social environment experienced by members of low-income households at both the individual and community levels.2227,29 Another possible mechanistic explanation might involve the association between low income and less formal education; less educated individuals may be less likely to acquire the knowledge and skills required for successful parental/self-management of symptoms.30,31 Education-related health outcomes often show a threshold pattern similar to the findings in our study.32 Yet another contributing factor may be the greater prevalence in low-income areas of physician practices with characteristics shown to be related to increased ED utilization (e.g. limited evening/weekend hours, lack of 24-hour phone access, no availability of nebulizer therapy).33 The association between low income and ED utilization, demonstrated even for children with access to subspecialty care, suggests that parents with low income may need specific support to overcome barriers to using physician services other than the ED.

A new finding is that the presence of tobacco smokers living in the same household as the patient was associated with an increase in acute chest syndrome diagnoses in the ED. The presence of a household tobacco smoker was associated with a 73% increase in acute chest syndrome events when compared to those that did not have household exposure. There is strong data regarding the association between environmental tobacco smoke and increased asthma morbidity,3437 and there is emerging data about its association with SCD morbidity.38,39 These data strengthen the evidence that environmental tobacco smoke is associated with SCD morbidity, particularly lung disease.

LIMITATIONS

There are several important differences between the patients in this study and the general population of children with SCD that affect the generalizability of the results. 1) Participants in this study are receiving SCD care at a tertiary medical center under the direction of a primary hematologist and a multi-disciplinary care team, whereas only 10% of Medicaid-enrolled children with SCD in the United States are under the regular care of a primary hematologist.40 2) Participants in this study consent to randomization in a clinical trial, thus they are likely to have greater trust and rapport with their providers than the general population. 3) Subjects in the trial cannot have evidence of overt stroke or be on hydroxyurea, which creates selection bias towards milder cases of SCD. These differences may have influenced some of the results of this study, thus limiting the generalizability of the findings. For example, in the general population, patients with SCD average 1.5 to 2.04 acute-care visits per patient-year,41 vs. 0.74 in the current study. It is likely that higher quality care and more intensive therapies were provided by the hematologists caring for these children. These differences may have masked differences (i.e. create bias towards the null hypothesis) in ED utilization rates based on health care delivery system that actually exist in the general population.

In this study, family income was a self-reported variable that may not accurately reflect true income. If patients were likely to self-report income higher than their true income, this would bias our results towards the null hypothesis. Additionally, our data cannot necessarily be extrapolated to assume that low socioeconomic status (a more global measure of a person’s income, education, occupation, and neighborhood disadvantage) will also be associated with increased ED utilization.

Some of the data were prospectively collected specifically for the SIT study (household income, number of people in household, and other sociodemographic and clinical variables); however, the rate of painful episodes, acute chest syndrome events, and diagnosis of asthma were based on chart review at each subject’s participating institution. All retrospectively collected variables were extracted with a rigorous prespecified protocol to minimize overestimation of outcome events. It is possible that ED visits were missed; however, this would tend to create bias towards the null hypothesis. Visits to EDs other than the SIT trial site were only recorded if the team knew about the event; no specific measures were taken to capture visits to other hospitals. We believe that failure to systematically record the ED visits that did not occur at the primary tertiary care center where the patient was followed would not bias the results away from the null hypothesis. Thus, the validity of the results is not significantly weakened.

Data on factors such as family income and environmental tobacco smoke were collected at the time of consent, but ED utilization data (the primary outcome) were collected for the three years prior to consent. The collection of outcome data for periods preceding the collection of exposure data creates the possibility that individuals were not exposed to a given risk factor (e.g. low income or tobacco smoke) for the entire duration of the sampling period. This does not significantly threaten the validity of the study, since this would tend to bias the results towards the null hypothesis. Individuals who were exposed to second hand smoke or to poverty for only part of the sampling period may have been part of the “exposed” group; the association would likely be stronger if these partial exposures could be accounted for. Additionally, children who had recently moved into the catchment area would not have ED visits recorded prior to their move. The vast majority of patients in the trial had been in the area for over three years because a requirement for entry into the study was an ongoing relationship with the hematology service.

CONCLUSIONS

We report that asthma, low income, and environmental tobacco smoke exposure are associated with higher rates of ED use for vasoocclusive complications of SCD in children enrolled in the SIT trial. These associations are likely to be even greater in the general population of children with SCD. A statistically significant difference was not found in the rates of ED utilization or the effect of income on ED utilization in countries with and without universal access to health care. Clinicians should carefully assess children with SCD for signs and symptoms of asthma and follow national guidelines for the management of asthma exacerbations. Future research is warranted to determine the magnitude of these associations in the general population of children with SCD. Targeted interventions to modify these risk factors should be evaluated in prospective trials.

Supplementary Material

Supp Data

Acknowledgements

Gary Yu, Columbia University, Mailman School of Public Health, for statistical analysis (financial support was given for this contribution); Joanne Brady, Columbia University, Departments of Anesthesiology and Epidemiology, for statistical analysis (no financial support was given for this contribution); Charles DiMaggio, PhD, MPH, Columbia University, Departments of Anesthesiology and Epidemiology, for statistical analysis (no financial support was given for this contribution); and Charles T. Quinn, MD, MS, Cincinnati Children’s Hospital Medical Center, Sharada A. Sarnaik, MD, Wayne State University School of Medicine, and David Newman, MD, Mount Sinai School of Medicine, for critical revisions of the manuscript for important intellectual content (no financial support was given for these contributions).

Supported by a grant from the National Institutes of Health (M.R.D., U01-NS42804).

Footnotes

Presented at the Society for Academic Emergency Medicine Annual Meeting. Boston MA, June 2011.

Disclosures: The authors have no potential conflicts of interest or other financial disclosures to report.

REFERENCES

1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38:S512–S521. [PubMed]
2. Hebbel RP, Boogaerts MA, Koresawa S, Jacob HS, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium as a determinant of vasocclusive severity in sickle cell disease. Trans Assoc Am Physicians. 1980;93:94–99. [PubMed]
3. Frenette PS. Sickle cell vasoocclusion: heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation. 2004;11:167–177. [PubMed]
4. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96:2451–2459. [PubMed]
5. Antonucci R, Walker R, Herion J, Orringer E. Enhancement of sickle erythrocyte adherence to endothelium by autologous platelets. Am J Hematol. 1990;34:44–48. [PubMed]
6. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129:507–516. [PubMed]
7. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129–151. [PubMed]
8. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148:94–101. [PubMed]
9. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855–1865. [PubMed]
10. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica. 2007;92:1115–1118. [PubMed]
11. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;108:2923–2927. [PubMed]
12. Glassberg J, Spivey JF, Strunk R, Boslaugh S, DeBaun MR. Painful episodes in children with sickle cell disease and asthma are temporally associated with respiratory symptoms. J Pediatr Hematol Oncol. 2006;28:481–485. [PMC free article] [PubMed]
13. Newaskar M, Hardy KA, Morris CR. Asthma in sickle cell disease. Sci World J. 2011;11:1138–1152. [PubMed]
14. Anim SO, Strunk RC, DeBaun MR. Asthma morbidity and treatment in children with sickle cell disease. Expert Rev Respir Med. 2011;5:635–645. [PMC free article] [PubMed]
15. Pritchard KA, Jr, Ou J, Ou Z, et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2004;286:L705–L714. [PubMed]
16. Pritchard KA, Feroah TR, Nandedkar SD, et al. Effects of experimental asthma on inflammation and lung mechanics in sickle cell mice. Am J Respir Cell Mol Biol. 2011;46(3):389–396. [PMC free article] [PubMed]
17. Field JJ, DeBaun MR. Asthma and sickle cell disease: two distinct diseases or part of the same process? Hematology Am Soc Hematol Educ Program. 2009:45–53. [PubMed]
18. Galea S, Tracy M, Hoggatt KJ, Dimaggio C, Karpati A. Estimated deaths attributable to social factors in the United States. Am J Public Health. 2011;101:1456–1465. [PubMed]
19. Mvundura M, Amendah D, Kavanagh PL, Sprinz PG, Grosse SD. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer. 2009;53:642–646. [PubMed]
20. Shatin D, Levin R, Ireys HT, Haller V. Health care utilization by children with chronic illnesses: a comparison of medicaid and employer-insured managed care. Pediatrics. 1998;102:e44. [PubMed]
21. Aisiku IP, Smith WR, McClish DK, et al. Comparisons of high versus low emergency department utilizers in sickle cell disease. Ann Emerg Med. 2009;53:587–593. [PubMed]
22. Casella JF, King AA, Barton B, et al. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol. 2010;27:69–89. [PubMed]
23. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997;89:1787–1792. [PubMed]
24. U.S. Department of Health & Human Services. The HHS poverty guidelines for the remainder of 2010. [Accessed Mar 12, 2012]; Available at: http://aspehhsgov/poverty/10povertyshtml.
25. Martinez FD. Links between pediatric and adult asthma. J Allergy Clin Immunol. 2001;107(5 Suppl):S449–S455. [PubMed]
26. Hebert PL, Taylor LT, Wang JJ, Bergman MA. Methods for using data abstracted from medical charts to impute longitudinal missing data in a clinical trial. Value Health. 2011;14:1085–1091. [PubMed]
27. Rubin DB. Multiple imputation for nonresponse in surveys. New York, NY: Wiley; 1987.
28. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83–89. [PubMed]
29. Adler N. Overview of Health Disparities. In: Thomson GE, Mitchell F, Williams M, editors. Examining the Health Disparities Research Plan of the National Institutes of Health: Unfinished Business. Washington DC: National Academies of Science; 2006. pp. 121–174. [PubMed]
30. National Center for Health Statistics. Hyattsville, MD: National Center for Health Statistics; 2004. Health, United States, 2004 with Chartbook on Trends in the Health of Americans. [PubMed]
31. Richardson LD, Norris M. Access to health and health care: how race and ethnicity matter. Mt Sinai J Med. 2010;77:166–177. [PubMed]
32. Backlund E, Sorlie PD, Johnson NJ. A comparison of the relationships of education and income with mortality: the National Longitudinal Mortality Study. Soc Sci Med. 1999;49:1373–1384. [PubMed]
33. Lowe RA, Localio AR, Schwarz DF, et al. Association between primary care practice characteristics and emergency department use in a medicaid managed care organization. Med Care. 2005;43:792–800. [PubMed]
34. Chilmonczyk BA, Knight GJ, Palomaki GE, Pulkkinen AJ, Williams J, Haddow JE. Environmental tobacco smoke exposure during infancy. Am J Public Health. 1990;80:1205–1208. [PubMed]
35. Chilmonczyk BA, Salmun LM, Megathlin KN, et al. Association between exposure to environmental tobacco smoke and exacerbations of asthma in children. N Engl J Med. 1993;328:1665–1669. [PubMed]
36. Cunningham J, O'Connor GT, Dockery DW, Speizer FE. Environmental tobacco smoke, wheezing, and asthma in children in 24 communities. Am J Respir Crit Care Med. 1996;153:218–224. [PubMed]
37. Strachan DP, Cook DG. Health effects of passive smoking. Part 6, Parental smoking and childhood asthma: longitudinal and case-control studies. Thorax. 1998;53:204–212. [PMC free article] [PubMed]
38. West DC, Romano PS, Azari R, Rudominer A, Holman M, Sandhu S. Impact of environmental tobacco smoke on children with sickle cell disease. Arch Pediatr Adolesc Med. 2003;157:1197–1201. [PubMed]
39. Cohen RT, DeBaun MR, Blinder MA, Strunk RC, Field JJ. Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease. Blood. 2010;115:3852–3854. [PubMed]
40. Raphael JL, Dietrich CL, Whitmire D, Mahoney DH, Mueller BU, Giardino AP. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer. 2009;52:263–267. [PubMed]
41. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303:1288–1294. [PubMed]